» Articles » PMID: 29925992

Reassessing B Cell Contributions in Multiple Sclerosis

Overview
Journal Nat Immunol
Date 2018 Jun 22
PMID 29925992
Citations 177
Authors
Affiliations
Soon will be listed here.
Abstract

There is growing recognition that B cell contributions to normal immune responses extend well beyond their potential to become antibody-producing cells, including roles at the innate-adaptive interface and their potential to modulate the responses of other immune cells such as T cells and myeloid cells. These B cell functions can have both pathogenic and protective effects in the context of central nervous system (CNS) inflammation. Here, we review recent advances in the field of multiple sclerosis (MS), which has traditionally been viewed as primarily a T cell-mediated disease, and we consider antibody-dependent and, particularly, emerging antibody-independent functions of B cells that may be relevant in both the peripheral and CNS disease compartments.

Citing Articles

Pediatric cerebrospinal fluid immune profiling distinguishes pediatric-onset multiple sclerosis from other pediatric-onset acute neurological disorders.

Espinoza D, Zrzavy T, Breville G, Thebault S, Marefi A, Mexhitaj I bioRxiv. 2025; .

PMID: 40060552 PMC: 11888486. DOI: 10.1101/2025.02.27.637541.


CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective.

Di Sabatino E, Ferraro D, Gaetani L, Emiliano E, Parnetti L, Di Filippo M J Neurol. 2025; 272(3):211.

PMID: 39960641 PMC: 11832686. DOI: 10.1007/s00415-025-12907-6.


Multiple Sclerosis: A Story of the Interaction Between Gut Microbiome and Components of the Immune System.

Mohsen E, Haffez H, Ahmed S, Hamed S, El-Mahdy T Mol Neurobiol. 2025; .

PMID: 39934561 DOI: 10.1007/s12035-025-04728-5.


Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis.

Chen H Front Pharmacol. 2025; 15:1521726.

PMID: 39917326 PMC: 11799251. DOI: 10.3389/fphar.2024.1521726.


The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system.

Zhou Y, Wu Y, Zhao X, Xu L, Sun M, Meng Z Front Immunol. 2025; 16:1515730.

PMID: 39917308 PMC: 11798770. DOI: 10.3389/fimmu.2025.1515730.